ClinicalTrials.gg
CompletedNCT01725087Updated Jul 15, 2021

Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.

A Phase 2 interventional study of Matching Placebo and Low Dose GRT6005 in Low Back Pain, sponsored by Tris Pharma, Inc.. Completed at 79 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-15.

Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,089
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Low Back Pain with a site in Germany — 5 open to participants now, 8 under way, 3 of them phase 3. Low Back Pain · Germany.

Enrollment
Largest of 54
1,089 · median 128
Started
2012
with 6 others
Phase 2
Only one
of the 59
Registered
26th of 59
by date

Among the 59 studies in Low Back Pain with a site in Germany, this one has the largest enrollment of the 54 interventional ones that give a count, is one of 7 that started in 2012, is the only one in phase 2, and was the 26th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

5 of the 59 studies in Low Back Pain with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Low Back Pain with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this trial is to evaluate the safety and efficacy of once daily orally administered GRT6005 in a total of 3 fixed doses compared to placebo in subjects with moderate to severe chronic Low Back Pain (LBP). The study includes a maximum of 21 days screening period followed by a 2-week titration period and 12-week maintenance double-blind treatment period and a 10-14 day safety follow up period. Patients who are eligible for the double-blind treatment period will be randomized to one of the following treatment groups: GRT6005 low-dose, GRT6005 medium dose, GRT6005 high-dose, Tapentadol or placebo.

03

Conditions studied

  • Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic Low Back Pain of non-malignant origin and present for at least 3 months.
  • Signed .
  • Pain intensity score of 5 or greater on the 11-point numeric rating scale (where 0 indicates "no pain" and 10 indicates "as bad as you can imagine").
  • On stable analgesic medications (non-opioid and/or opioid medications) for chronic low back pain with regular intake for at least 3 months and dissatisfied with current analgesic treatment.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant or are breastfeeding.
  • Presence of risk factors for Torsade de Pointes.
  • Any disease or laboratory findings that may affect efficacy or safety assessments or may compromise the safety during trial participation, e.g., significant unstable cardiac, vascular, pulmonary, gastrointestinal, endocrine, metabolic, neurological, or psychiatric disorders.
  • History of acute hepatitis within the past 3 months or chronic hepatitis or a positive result on anti-hepatitis A antibody, surface antigen, or anti- antibody. History of (HIV) infection.
  • History of seizure disorder.
  • Chronic low back pain potentially associated with a specific spinal cause.
  • Surgery or painful procedure during or within 3 months of enrollment.
  • Conditions that contribute and confound the assessment of pain.
  • Subjects with impaired renal function.
  • Subjects with impaired hepatic functionality.
  • Neuromodulation.
  • Cancer.
  • Clinically relevant history of , allergy or to any of the Medicinal Products' , paracetamol/acetaminophen, tapentadol Hydrochloride, or opioid analgesics (or excipients).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,089 participants (actual)

Study arms

  • Placebo comparator
    Matching Placebo

    Twice daily oral administration of matching placebo for 14 weeks

    Drug: Matching Placebo

  • Experimental
    Low Dose GRT6005

    Once daily GRT6005 low dose oral administration for 12 weeks with a titration period of 2 weeks.

    Drug: Low Dose GRT6005

  • Experimental
    Medium Dose GRT6005

    Once daily GRT6005 medium dose oral administration for 12 weeks with a titration period of 2 weeks.

    Drug: Medium Dose GRT6005

  • Experimental
    High Dose GRT6005

    Once daily GRT6005 high dose oral administration for 12 weeks with a titration period of 2 weeks.

    Drug: High Dose GRT6005

  • Active comparator
    Tapentadol

    Twice daily oral administration of Tapentadol for 12 weeks with a titration period of 2 weeks.

    Drug: Tapentadol

Interventions

06

What researchers measure

Primary outcomes

  1. European Union: the change from baseline pain to the weekly average 24-hour pain during the entire 12 weeks of the maintenance phase of the double-blind Treatment Period.

    Time frame: Baseline to End of Treatment (Week 14)

  2. United States: the change from baseline pain to the average 24-hour pain during Week 12 of the maintenance phase.

    Time frame: Baseline to End of Treatment (Week 14)

07

Study locations

79 sites
  • AT003
    Senftenberg, 3541, Austria
  • AT004
    Wien, 1060, Austria
  • AT001
    Wien, 1090, Austria
  • AT005
    Wien, 1100, Austria
  • AT006
    Wien, 1100, Austria
  • BE001
    Bruxelles, 1070, Belgium
  • BE002
    Edegem, 2650, Belgium
  • BE004
    Genk, 3600, Belgium
  • DK004
    Aalborg, 9100, Denmark
  • DK001
    Frederiksberg, 2000, Denmark
  • Site DK002
    Glostrup, 2600, Denmark
  • DK003
    Odense, 5000, Denmark
  • FI005
    Kokkola, 67100, Finland
  • FI001
    Kuopio, 70210, Finland
  • FI003
    Lahti, 15110, Finland
  • DE005
    Bad Nauheim, 61231, Germany
  • DE014
    Berlin, 10117, Germany
  • DE018
    Berlin, 13125, Germany
  • DE011
    Bochum, 44787, Germany
  • DE015
    Böhlen, 04564, Germany
  • DE007
    Dresden, 01069, Germany
  • DE016
    Essen, 45355, Germany
  • DE001
    Hamburg, 22415, Germany
  • DE006
    Hamburg, 22767, Germany
  • DE008
    Hannover, 30159, Germany
  • DE002
    Leipzig, 04103, Germany
  • DE019
    Leipzig, Germany
  • DE009
    Mosbach, 74821, Germany
  • DE004
    Munich, 80333, Germany
  • DE013
    Rodgau, 63110, Germany
  • DE017
    Wiesbaden, 65185, Germany
  • HU010
    Baja, 6500, Hungary
  • HU011
    Budapest, 1036, Hungary
  • HU015
    Budapest, 1084, Hungary
  • HU005
    Budapest, 1113, Hungary
  • HU012
    Budapest, 8800, Hungary
  • HU008
    Békéscsaba, Hungary
  • HU003
    Kecskemet, 6000, Hungary
  • HU002
    Kiskunfélegyháza, 6100, Hungary
  • HU001
    Mako, 6900, Hungary
  • HU009
    Nagykanizsa, 8800, Hungary
  • HU014
    Nyiregyhaza, 4400, Hungary
  • HU004
    Szekszárd, 7100, Hungary
  • NL003
    Almere, 1311RL, Netherlands
  • NL002
    Eindhoven, 5623EJ, Netherlands
  • NL005
    Tiel, 4002 WP, Netherlands
  • PL002
    Elblag, 82-300, Poland
  • PL015
    Gdynia, 81-338, Poland
  • PL006
    Gdynia, 81-384, Poland
  • PL001
    Katowice, 40-040, Poland
  • PL014
    Katowice, 40-954, Poland
  • PL008
    Krakow, 30-510, Poland
  • PL013
    Krakow, 30-510, Poland
  • PL011
    Krakow, 31-159, Poland
  • PL009
    Lublin, 20-605, Poland
  • PL016
    Poznan, 60-773, Poland
  • PL018
    Poznan, 61-397, Poland
  • PL012
    Warszawa, 01-868, Poland
  • PL004
    Warszawa, 62-3832, Poland
  • PL010
    Wroclaw, 51-162, Poland
  • PL017
    Wroclaw, 53-114, Poland
  • PL005
    Zgierz, 95-100, Poland
  • ES002
    Barcelona, 08540, Spain
  • ES006
    Barcelona, 8023, Spain
  • ES004
    La Coruna, 15006, Spain
  • ES001
    Madrid, 28046, Spain
  • ES013
    Madrid, 28050, Spain
  • ES008
    Málaga, 29009, Spain
  • ES003
    Oviedo, 33009, Spain
  • ES011
    Oviedo, 33013, Spain
  • ES005
    Santiago de Compostela, 15705, Spain
  • ES007
    Sevilla, 41071, Spain
  • SE001
    Skene, 51162, Sweden
  • SE002
    Stockholm, 11522, Sweden
  • SE004
    Vällingby, Sweden
  • GB002
    Liverpool, L22 0LG, United Kingdom
  • GB005
    London, SE1 7EH, United Kingdom
  • GB003
    Manchester, M15 6SX, United Kingdom
  • GB004
    Plymouth, PL6 8DH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2012
First posted
Nov 12, 2012
Start
Nov 2012
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Last update
Jul 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01725087
Lead sponsor
Tris Pharma, Inc.
Collaborators
Forest Laboratories
Responsible party
Sponsor
First posted
Nov 12, 2012
Start date
Nov 2012
Primary completion
Jul 2014
Completion
Jul 2014
Last update
Jul 15, 2021

Study contacts

Study Director
study chair · Grünenthal GmbH
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cebranopadol

Start the discussion